Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences

Resectable non-small cell lung cancer (NSCLC) continues to pose significant challenges with high recurrence and mortality rates, despite traditional platinum-based chemotherapy yielding only an approximate 5% improvement in 5-year overall survival when administered preoperatively or postoperatively....

Full description

Bibliographic Details
Published in:	Current Oncology
Main Authors:	Thoma’ Dario Clementi, Francesca Colonese, Stefania Canova, Maria Ida Abbate, Luca Sala, Francesco Petrella, Gabriele Giuseppe Pagliari, Diego Luigi Cortinovis
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Subjects:	perioperative in lung cancer resectable/early-stage NSCLC chemo-immunotherapies for NSCLC neoadjuvant ICIs
Online Access:	https://www.mdpi.com/1718-7729/32/7/397

Similar Items

The role of immunotherapy in early-stage and metastatic NSCLC
by: Attila Lieber, et al.
Published: (2024-07-01)

Recent Advances in Perioperative Immunotherapies in Lung Cancer
by: Shota Fukuda, et al.
Published: (2023-09-01)

Impact of concurrent medications on the outcome of immunotherapy in non‐small cell lung carcinoma
by: Jun Yamada, et al.
Published: (2024-05-01)

Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy
by: Ulas Kumbasar, et al.
Published: (2025-06-01)

Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy
by: Shuta Ohara, et al.
Published: (2025-08-01)

Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
by: Lavinia Gatteschi, et al.
Published: (2021-10-01)

Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery
by: Hyein Jeon, et al.
Published: (2024-06-01)

The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer
by: Gaia Passarella, et al.
Published: (2025-01-01)

Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
by: Tongtong Zhang, et al.
Published: (2023-10-01)

Effect of Perioperative Factors on Short-Term Outcomes in Patients with Non-Small Cell Lung Cancer Over 60 Years of Age
by: Zhu W, et al.
Published: (2024-11-01)

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
by: Yunfeng Ni, et al.
Published: (2023-04-01)

Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis
by: Jian Qin, et al.
Published: (2023-05-01)

Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer
by: Thomas Hansen, et al.
Published: (2024-09-01)

Blocking copper transporter protein-dependent drug efflux with albumin-encapsulated Pt(IV) for synergistically enhanced chemo-immunotherapy
by: Man Fang, et al.
Published: (2025-03-01)

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
by: Belén Sierra Rodero, et al.
Published: (2025-12-01)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Gen Lin, et al.
Published: (2024-02-01)

Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer
by: Liling Huang, et al.
Published: (2025-05-01)

Perioperative immune checkpoint inhibitors in elderly patients with resectable NSCLC: a systematic review and meta-analysis
by: Yue Cao, et al.
Published: (2025-09-01)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
by: Paolo Borghetti, et al.
Published: (2022-07-01)

Lobe‐specific analysis of perioperative chemotherapy for non‐small cell lung cancer patients
by: Xi Lei, et al.
Published: (2023-08-01)

Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
by: Zheng Yuan, et al.
Published: (2021-08-01)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
by: Yurong Peng, et al.
Published: (2023-01-01)

Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer
by: Bo Yang, et al.
Published: (2025-03-01)

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
by: Yurong Peng, et al.
Published: (2023-03-01)

A Meta‐Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non‐Small Cell Lung Cancer
by: Xinru Sun, et al.
Published: (2024-10-01)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
by: Min Fang, et al.
Published: (2023-01-01)

Three‐Year Follow‐Up of the Phase II Trial for Resectable Non‐Small‐Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD‐NeoFOUR Trial
by: Zhiyuan Gao, et al.
Published: (2025-08-01)

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study
by: Luigi Liguori, et al.
Published: (2024-11-01)

Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report
by: Sabine Raimann, MD, et al.
Published: (2025-06-01)

Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?
by: J. Humberto Rodriguez-Quintero, MD, MPH, et al.
Published: (2025-01-01)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
by: Yuntao Wang, et al.
Published: (2022-05-01)

A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer
by: Shaoqiu Chen, et al.
Published: (2024-11-01)

Neoadjuvant Selpercatinib for Stage IIIA Primary Pulmonary Adenocarcinoma With RET Fusion: A Case Report
by: Zihan Cui, et al.
Published: (2025-10-01)

Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer
by: Sara Frida Cohen, et al.
Published: (2024-11-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
by: Xin Liao, et al.
Published: (2024-10-01)

Perioperative Treatment in EGFR‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives
by: Xiaobei Guo, et al.
Published: (2025-02-01)

A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China
by: Hongmei Li, et al.
Published: (2024-11-01)

Development and validation of a nomogram for predicting immune-related thyroid dysfunction during immunotherapy in non-small cell lung cancer: a prospective cohort study in China
by: Qianjie Xu, et al.
Published: (2025-07-01)

Serum KL-6 levels reflect the severity of interstitial lung disease caused by immune checkpoint inhibitors
by: Xiaoping Li, et al.
Published: (2025-01-01)

Editorial: Optimal perioperative management of urothelial carcinoma
by: Ariane Holzman, et al.
Published: (2023-05-01)